ELI Radiopharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ELI Radiopharma - overview
Established
2024
Location
Hangzhou, Zhejiang, China
Primary Industry
Pharmaceuticals
About
Founded in 2024 and based in Hangzhou, China, Hangzhou Eli Radiopharma Co. , Ltd. , trading as ELI Radiopharma, is a pharmaceutical technology company that focuses on advancing precision medicine through innovative radiopharmaceutical development. In March 2026, ELI Radiopharma raised nearly CNY 100 million in venture funding from Beike Fund, Longtai Investment, Yicheng Investment, and Hongsheng Capital.
The company focus on integrated diagnostic and therapeutic solutions for neurological diseases and oncology, aiming to improve patient outcomes globally. The company’s revenue is generated by providing pharmaceutical R&D and technical consulting services. The company will use the latest funding to support the molecular discovery, technology platform construction, and clinical translation of the company's new target projects, helping the innovative pipeline to steadily move towards the clinical stage.
Current Investors
Hangzhou Lula Asset Management, TigerYeah Capital, Tailong VC
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.eliradiopharma.com/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.